Literature DB >> 2802858

Efficacy and benefit of mediastinal computed tomography as a selection method for mediastinoscopy.

M Thermann1, R Bluemm, U Schroeder, E Wassmuth, R Dohmann.   

Abstract

In 95 consecutive patients with proven or suspected bronchial carcinoma, computed tomographic evaluation of the upper mediastinum for N2 disease was performed prospectively. Patients with positive results underwent mediastinoscopy. Patients with perinodal N2 or N3 disease at mediastinoscopy were not considered candidates for operation. The mediastinum was declared negative only when intraoperative mediastinal lymph node dissection showed tumor-free nodes. Of the 95 patients, 12 had benign lesions, 14 were excluded from further evaluation because the lymph node status of the mediastinum was not proven intraoperatively, and 6 others were excluded from the final evaluation because of violation of the protocol. Twenty-two of the 75 remaining patients had a positive computed tomographic scan and underwent mediastinoscopy. Fourteen patients with positive results were considered to have inoperable disease. Fifty-three patients (70.7%) did not undergo mediastinoscopy. We performed seven probably incomplete resections, two for palliative reasons, and two thoracotomies without resection in patients with N2 disease. A policy of routine mediastinoscopy would have prevented only 5% of the thoracotomies performed in patients with lung cancer.

Entities:  

Mesh:

Year:  1989        PMID: 2802858     DOI: 10.1016/s0003-4975(10)66864-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Cost-effectiveness associated with the diagnosis and staging of non-small-cell lung cancer.

Authors:  H Osada; K Kojima; H Tsukada; Y Nakajima; K Imamura; J Matsumoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-01

2.  Intranodal and extranodal tumour growth in early metastasised non-small cell lung cancer: problems in histological diagnosis.

Authors:  P H Theunissen; E C Bollen; J Koudstaal; F B Thunnissen
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.